The non-postoperative pain management market is witnessing steady growth, driven by the increasing prevalence of acute and chronic pain conditions, rising demand for effective non-surgical pain therapies, and greater emphasis on opioid-sparing treatment strategies. Advances in non-opioid analgesics, targeted therapies, and innovative drug delivery technologies are expanding the treatment landscape. In addition, the expected launch of emerging therapies such as TK-254Rx (esflurbiprofen transdermal) (Teikoku Pharma), RizaFilm (rizatriptan) (Gensco Pharma), ELYXYB (Scilex Holding Company), and others will further propel the market growth.
The non-postoperative pain management market is witnessing steady growth, driven by the increasing prevalence of acute and chronic pain conditions, rising demand for effective non-surgical pain therapies, and greater emphasis on opioid-sparing treatment strategies. Advances in non-opioid analgesics, targeted therapies, and innovative drug delivery technologies are expanding the treatment landscape. In addition, the expected launch of emerging therapies such as TK-254Rx (esflurbiprofen transdermal) (Teikoku Pharma), RizaFilm (rizatriptan) (Gensco Pharma), ELYXYB (Scilex Holding Company), and others will further propel the market growth.